Pricing Log in Create free account
Saturday 17 October 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.

112.95 0.32 −0.28%
Market cap
$23.0B
P/E
13.9×
Fwd P/E
15.6×
Dividend yield
—
F-score
9/9
Altman Z
8.57
Beneish M
−2.43
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Incyte Corporation (INCY) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Aug 31, 2026 8.01 Other events
10-Q Jun 30, 2026 P1I2: 8 added · 4 removed · 34 modified
P2I1A: 4 added · 22 modified
8-K Jul 28, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Jun 22, 2026 8.01 Other events
8-K Jun 8, 2026 5.07 Submission of matters to a vote of security holders
8-K Jun 8, 2026 8.01 Other events
10-Q Mar 31, 2026
8-K Apr 28, 2026 2.02 Results of operations and financial condition
8-K Mar 26, 2026 5.02 Departure or appointment of directors or officers Officer departure
8-K Mar 25, 2026 5.02 Departure or appointment of directors or officers; 9.01 Financial statements and exhibits
8-K Feb 27, 2026 8.01 Other events
10-K Dec 31, 2025 1: 36 added · 94 removed · 76 modified
1A: 4 added · 1 removed · 82 modified
7: 9 added · 8 removed · 36 modified
8-K Feb 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Dec 10, 2025 5.02 Departure or appointment of directors or officers
10-Q Sep 30, 2025
8-K Oct 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 30, 2025 5.02 Departure or appointment of directors or officers
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.